Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Aug 10;6:31071. doi: 10.1038/srep31071

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016, The Author(s)

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

(A) Among CCBE1 low expression intermediate- and high risk GIST patients, there was no significant difference in disease-free survival between the groups with or without imatinib adjuvant treatment. (B) Among CCBE1 high expression intermediate- and high risk GIST patients, there was no significant difference in disease-free survival between the groups with or without imatinib adjuvant treatment. (C) Among imatinib treatment intermediate- and high risk GIST patients, there was no significant difference in disease-free survival between the CCBE1 high and low expression groups, but a slight decrease of DFS in CCBE1 high expression groups compared with CCBE1 low expression groups. (D) In all patients with surgery treatment only, patients had a poorer DFS in CCBE1 high expression groups compared with CCBE1 low expression groups (p = 0.004).